David M Mott - Net Worth and Insider Trading
David M Mott Net Worth
The estimated net worth of David M Mott is at least $1.4 Billion dollars as of 2024-04-19. David M Mott is the Director, 10% Owner of Tesaro Inc and owns about 10,434,803 shares of Tesaro Inc (TSRO) stock worth over $782 Million. David M Mott is the 10% Owner of Rhythm Pharmaceuticals Inc and owns about 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) stock worth over $187 Million. David M Mott is also the 10% Owner of Ra Pharmaceuticals Inc and owns about 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) stock worth over $167 Million. Besides these, David M Mott also holds Mirum Pharmaceuticals Inc (MIRM) , Adaptimmune Therapeutics PLC (ADAP) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Regulus Therapeutics Inc (RGLS) , Epizyme Inc (EPZM) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Novavax Inc (NVAX) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , Genocea Biosciences Inc (GNCAQ) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) . Details can be seen in David M Mott's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that David M Mott has not made any transactions after 2022-11-17 and currently still holds the listed stock(s).
Transaction Summary of David M Mott
David M Mott Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, David M Mott owns 52 companies in total, including Epizyme Inc () , Adaptimmune Therapeutics PLC () , and Novavax Inc () among others .
Click here to see the complete history of David M Mott’s form 4 insider trades.
Insider Ownership Summary of David M Mott
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
Epizyme Inc | 2021-03-26 | director | |
Adaptimmune Therapeutics PLC | 2020-07-01 | director | |
Novavax Inc | 2021-09-23 | director | |
Mersana Therapeutics Inc | 2020-04-07 | director | |
Ardelyx Inc | 2022-11-17 | director | |
Imara Inc | 2022-02-23 | director | |
Casper Sleep Inc | 2020-02-06 | 10 percent owner | |
Black Diamond Therapeutics Inc | 2020-01-29 | 10 percent owner | |
Regulus Therapeutics Inc | 2019-05-07 | 10 percent owner | |
Sprout Social Inc | 2019-12-12 | 10 percent owner | |
Galera Therapeutics Inc | 2019-11-06 | 10 percent owner | |
Oyster Point Pharma Inc | 2019-10-30 | 10 percent owner | |
Cloudflare Inc | 2019-09-12 | 10 percent owner | |
Mirum Pharmaceuticals Inc | 2019-07-22 | 10 percent owner | |
Genocea Biosciences Inc | 2019-06-24 | 10 percent owner | |
Nightstar Therapeutics PLC | 2019-06-07 | director & 10 percent owner | |
Trevi Therapeutics Inc | 2019-05-09 | 10 percent owner | |
AVEO Pharmaceuticals Inc | 2019-04-08 | 10 percent owner | |
Tesaro Inc | 2019-01-22 | director & 10 percent owner | |
Ra Pharmaceuticals Inc | 2018-12-14 | 10 percent owner | |
Millendo Therapeutics Inc | 2018-12-07 | 10 percent owner | |
PhaseBio Pharmaceuticals Inc | 2018-10-17 | 10 percent owner | |
Marker Therapeutics Inc | 2018-10-17 | 10 percent owner | |
Elastic NV | 2018-10-04 | 10 percent owner | |
MuleSoft Inc | 2018-05-01 | 10 percent owner | |
Surface Oncology Inc | 2018-04-23 | 10 percent owner | |
TRACON Pharmaceuticals Inc | 2018-03-27 | 10 percent owner | |
Cascadian Therapeutics Inc | 2018-03-09 | 10 percent owner | |
ARCA biopharma Inc | 2018-02-26 | 10 percent owner | |
Appian Corp | 2017-11-27 | 10 percent owner | |
Synlogic Inc | 2015-09-30 | 10 percent owner | |
Strongbridge Biopharma PLC | 2018-01-01 | 10 percent owner | |
X4 Pharmaceuticals Inc | 2017-11-20 | 10 percent owner | |
Care.com Inc | 2017-11-06 | 10 percent owner | |
Rhythm Pharmaceuticals Inc | 2017-10-10 | 10 percent owner | |
Achaogen Inc | 2016-12-19 | 10 percent owner | |
Sorrento Tech Inc | 2016-09-21 | 10 percent owner | |
Interleukin Genetics Inc | 2016-07-29 | 10 percent owner | |
Avalo Therapeutics Inc | 2015-10-14 | 10 percent owner | |
Champions Oncology Inc | 2015-03-11 | 10 percent owner | |
Box Inc | 2015-01-22 | 10 percent owner | |
Cvent Inc | 2014-11-25 | 10 percent owner | |
Dermira Inc | 2014-10-08 | 10 percent owner | |
Loxo Oncology Inc | 2014-08-06 | 10 percent owner | |
Aerohive Networks Inc | 2014-04-02 | 10 percent owner | |
GlycoMimetics Inc | 2014-01-09 | 10 percent owner | |
Clovis Oncology Inc | 2011-11-21 | 10 percent owner | |
Workday Inc | 2012-10-11 | 10 percent owner | |
Millennial Media Inc | 2012-10-29 | 10 percent owner | |
Tempest Therapeutics Inc | 2018-12-07 | 10 percent owner | |
Enliven Therapeutics Inc | 2020-03-11 | director | |
Genocea Biosciences Inc | 2018-01-19 | 10 percent owner |
David M Mott Latest Holdings Summary
David M Mott currently owns a total of 23 stocks. Among these stocks, David M Mott owns 10,434,803 shares of Tesaro Inc (TSRO) as of March 6, 2018, with a value of $782 Million and a weighting of 55.56%. David M Mott owns 4,909,956 shares of Rhythm Pharmaceuticals Inc (RYTM) as of October 10, 2017, with a value of $187 Million and a weighting of 13.29%. David M Mott also owns 3,490,073 shares of Ra Pharmaceuticals Inc (RARX) as of October 31, 2016, with a value of $167 Million and a weighting of 11.9%. The other 20 stocks Mirum Pharmaceuticals Inc (MIRM) , Adaptimmune Therapeutics PLC (ADAP) , AVEO Pharmaceuticals Inc (AVEO) , Millennial Media Inc (MM) , Trevi Therapeutics Inc (TRVI) , Ardelyx Inc (ARDX) , Surface Oncology Inc (SURF) , Mersana Therapeutics Inc (MRSN) , Imara Inc (IMRA) , Regulus Therapeutics Inc (RGLS) , Epizyme Inc (EPZM) , Dermira Inc (DERM) , Interleukin Genetics Inc (ILIU) , Novavax Inc (NVAX) , Achaogen Inc (AKAOQ) , Clovis Oncology Inc (CLVSQ) , TRACON Pharmaceuticals Inc (TCON) , Genocea Biosciences Inc (GNCAQ) , ARCA biopharma Inc (ABIO) , Appian Corp (APPN) have a combined weighting of 19.25% among all his current holdings.
Latest Holdings of David M Mott
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
TSRO | Tesaro Inc | 2018-03-06 | 10,434,803 | 74.96 | 782,192,833 |
RYTM | Rhythm Pharmaceuticals Inc | 2017-10-10 | 4,909,956 | 38.11 | 187,118,423 |
RARX | Ra Pharmaceuticals Inc | 2016-10-31 | 3,490,073 | 47.99 | 167,488,603 |
MIRM | Mirum Pharmaceuticals Inc | 2019-07-22 | 4,186,243 | 23.57 | 98,669,748 |
ADAP | Adaptimmune Therapeutics PLC | 2020-01-24 | 102,478,668 | 0.90 | 92,066,835 |
AVEO | AVEO Pharmaceuticals Inc | 2019-04-08 | 2,524,387 | 15.00 | 37,865,805 |
MM | Millennial Media Inc | 2012-10-29 | 8,196,614 | 1.75 | 14,344,075 |
TRVI | Trevi Therapeutics Inc | 2019-05-09 | 4,438,562 | 2.68 | 11,895,346 |
ARDX | Ardelyx Inc | 2022-11-17 | 1,166,765 | 6.44 | 7,513,967 |
SURF | Surface Oncology Inc | 2018-04-23 | 3,312,877 | 1.07 | 3,544,778 |
MRSN | Mersana Therapeutics Inc | 2020-04-07 | 538,599 | 3.34 | 1,796,228 |
IMRA | Imara Inc | 2022-02-23 | 229,224 | 6.32 | 1,448,696 |
RGLS | Regulus Therapeutics Inc | 2019-05-07 | 205,245 | 2.21 | 453,591 |
EPZM | Epizyme Inc | 2021-03-26 | 257,859 | 1.47 | 379,053 |
DERM | Dermira Inc | 2014-10-02 | 17,241 | 18.75 | 323,269 |
ILIU | Interleukin Genetics Inc | 2016-07-29 | 55,418,811 | 0.00 | 249,385 |
NVAX | Novavax Inc | 2021-09-23 | 40,000 | 3.90 | 155,800 |
AKAOQ | Achaogen Inc | 2016-12-19 | 5,215,128 | 0.03 | 130,378 |
CLVSQ | Clovis Oncology Inc | 2011-11-21 | 3,419,671 | 0.02 | 51,295 |
TCON | TRACON Pharmaceuticals Inc | 2018-03-27 | 17,330 | 2.12 | 36,740 |
GNCAQ | Genocea Biosciences Inc | 2019-06-24 | 7,225,676 | 0.00 | 723 |
ABIO | ARCA biopharma Inc | 2018-02-26 | 0 | 3.25 | 0 |
APPN | Appian Corp | 2017-11-27 | 0 | 34.88 | 0 |
Holding Weightings of David M Mott
David M Mott Form 4 Trading Tracker
According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Tesaro Inc (TSRO) over the past 5 years. The most-recent trade in Tesaro Inc is the acquisition of 145,532 shares on March 6, 2018, which cost David M Mott around $8 Million.
According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Rhythm Pharmaceuticals Inc (RYTM) over the past 5 years. The most-recent trade in Rhythm Pharmaceuticals Inc is the acquisition of 550,000 shares on October 10, 2017, which cost David M Mott around $9 Million.
According to the SEC Form 4 filings, David M Mott has made a total of 0 transactions in Ra Pharmaceuticals Inc (RARX) over the past 5 years. The most-recent trade in Ra Pharmaceuticals Inc is the sale of 435 shares on October 31, 2016, which brought David M Mott around $5,655.
More details on David M Mott's insider transactions can be found in the Insider Trading History of David M Mott table.Insider Trading History of David M Mott
- 1
David M Mott Trading Performance
GuruFocus tracks the stock performance after each of David M Mott's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by David M Mott is 6.8%. GuruFocus also compares David M Mott's trading performance to market benchmark return within the same time period. The performance of stocks bought by David M Mott within 3 months outperforms 30 times out of 56 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how David M Mott's insider trading performs compared to the benchmark.
Performance of David M Mott
Average Return
9.64%
Outperforming Transactions
36%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | 7.23 | 6.8 | 10.09 | 9.64 | -25.07 | -21.01 |
Relative Return to S&P 500(%) | 6.27 | 3.75 | 3.17 | -3.68 | -37.27 | -34.65 |
David M Mott Ownership Network
Ownership Network List of David M Mott
Ownership Network Relation of David M Mott
David M Mott Owned Company Details
What does Epizyme Inc do?
Who are the key executives at Epizyme Inc?
David M Mott is the director of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .
Epizyme Inc () Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc () in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Epizyme Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.
Epizyme Inc Insider Transactions
David M Mott Mailing Address
Above is the net worth, insider trading, and ownership report for David M Mott. You might contact David M Mott via mailing address: 1119 St. Paul Street, Baltimore Md 21202.